Haplotype editing with CRISPR/Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL.
Dua PH, Simon BMJ, Marley CBE, Feliciano CM, Watry HL, Steury D, Abraham A, Gilbertson EN, Ramey GD, Capra JA, Conklin BR, Judge LM.
Dua PH, et al. Among authors: simon bmj.
bioRxiv [Preprint]. 2024 Dec 22:2024.12.20.629813. doi: 10.1101/2024.12.20.629813.
bioRxiv. 2024.
PMID: 39763989
Free PMC article.
Preprint.